NCT05757505招募中不适用
The Efficacy and Safety of the Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial
Ton-Bridge Medical Tech. Co., Ltd13 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年5月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 13
- 主要终点
- Incidence of any stroke and death within 30 days
研究概览
简要总结
The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of symptomatic intracranial atherosclerotic stenosis.
详细描述
This is a prospective, multicenter, randomized controlled, non-inferiority clinical trial carried out in 13 centers throughout China. 200 subjects with symptomatic intracranial atherosclerotic stenosis will be treated with the Intracranial Stent (Zhuhai Tonbridge Medical Tech. Co., Ltd.) or the Wingspan Stent System (Stryker Neurovascular) for the expansion of vascular stenosis site. The primary objective of this study is to evaluate the effectiveness and safety of the intracranial stent for endovascular treatment of symptomatic intracranial atherosclerotic stenosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75;
- •Subjects with symptomatic intracranial atherosclerotic stenosis who do not respond to antiplatelet therapy or have poor compensation of collateral circulation and hypoperfusion in the offending vessel blood supply;
- •The last onset time of TIA is not limited or the last onset of ischemic stroke is more than 2 weeks;
- •The lesion is confirmed to be located in intracranial large arteries, including intracranial segment of the internal carotid artery, middle cerebral artery, intracranial segment of vertebral artery and the basilar artery;
- •Target vessel diameter≥2.0mm and ≤4.5mm, lesion length ≤33mm;
- •Stenosis degree of intracranial arteries≥70% and ≤99% measured by intracranial angiography (WASID method);
- •Intracranial artery stenosis which requiring interventional treatment is a single lesion;
- •Subjects have at least 1 atherosclerotic plaque risk factor including hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, and smoking history;
- •mRS≤2 before enrollment;
- •Voluntarily participate in this study and sign the informed consent form, can complete examinations and follow-ups in accordance with the requirements of the protocol during the clinical trial.
排除标准
- •Intracranial arterial stenosis caused by non-atherosclerotic lesions: such as arterial dissection, moyamoya disease, vasculitis, active arteritis, etc.;
- •Preoperative MRI shows only perforator infarction in the target lesion;
- •Preoperative CT or MRI indicates the presence of post-infarct hemorrhagic transformation in the target vascular, or a history of subarachnoid, subdural, and epidural hemorrhage within 30 days before procedure, or the presence of untreated chronic subdural hematoma (≥5mm);
- •Severe calcification of target vessels; or target vessel tortuosity or other reasons will make experimental device difficult to reach the target lesion position;
- •There is more than 70% stenosis in the distal intracranial large vessels or proximal intracranial and extracranial large vessels of the target vessels, and the presence of unidentified responsible lesions;
- •Subjects have a major surgery within 30 days before procedure or intend to be hospitalized for other procedure within 6 months after procedure;
- •Intracranial tumors or intracranial arteriovenous malformations, or distal and proximal target vessels combined with aneurysms;
- •The target lesion has a history of stent implantation;
- •It is suspected that there is severe allergy or contraindication to aspirin, clopidogrel, heparin, contrast media, nitinol and other drugs and devices related to endovascular therapy;
- •There is an underlying source of cardiac thrombus, such as atrial fibrillation, left ventricular thrombus, myocardial infarction within 30 days;
- •Subjects with an INR > 1.5 or the presence of nonmodifiable bleeding factors;
- •Medically uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg);
- •Severe comorbid conditions or unstable conditions, such as severe heart failure, pulmonary failure, or renal failure (serum creatinine >3.0 mg/dL (264μmol/L)), severe liver insufficiency (ALT or AST >3 times normal), and malignancy;
- •Life expectancy is less than two years;
- •Women who are pregnant or breastfeeding;
- •Subjects unable to complete follow-up due to cognitive impairment, mood disorder, or mental illness;
- •Subjects who are enrolled in other clinical trials of drugs/devices and have not yet met the primary endpoint;
- •Other circumstances which investigators do not consider are appropriate for intracranial stent treatment.
结局指标
主要结局
Incidence of any stroke and death within 30 days
时间窗: 30±7 days post-procedure
Stroke includes both ischemic and hemorrhagic stroke. Death includes death due to any cause.
次要结局
- Procedural success rate(intra-procedure)
- Incidence of serious adverse events (SAE) at 30 days, 6 months, 12 months, and 24 months(Through 24 months post-procedure)
- Ratio of mRS 0-2 at 30 days, 6 months, 12 months, and 24 months(30±7 days, 6 months±60 days, 12 months±30 days, and 24 months±30 days post-procedure)
- Incidence of ischemic stroke in non-target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months(31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure)
- Incidence of adverse events (AE) at 30 days, 6 months, 12 months, and 24 months(Through 24 months post-procedure)
- Device success rate(intra-procedure)
- Incidence of in-stent restenosis at 6 months, 12 months, and 24 months(6 months±60 days, 12 months±30 days, and 24 months±30 days post-procedure)
- Incidence of symptomatic in-stent restenosis at 6 months, 12 months, and 24 months(6 months±60 days, 12 months±30 days, and 24 months±30 days post-procedure)
- Incidence of device deficiency(After use of device to end of study, assess up to 24 months)
- Mortality at 31 days to 6 months, 6 to 12 months, and 12 to 24 months(31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure)
- Incidence of ischemic stroke in the target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months(31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure)
- Incidence of any hemorrhagic stroke at 31 days to 6 months, 6 to 12 months, and 12 to 24 months(31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure)
研究者
研究点 (13)
Loading locations...
相似试验
尚未招募
不适用
The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic StenosisIntracranial AtherosclerosisNCT05593224Zhuhai Tonbridge Medical Tech. Co., Ltd.156
进行中（未招募）
不适用
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery StenosisCarotid Artery StenosisNCT06365697Ton-Bridge Medical Tech. Co., Ltd188
已完成
3 期
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)Coronary DiseaseNCT00165035Cordis Corporation1,701
已完成
早期 1 期
Prospective Study on Safety and Efficacy of Stenting for Chronic Middle Cerebral Artery Occlusion With Limb DysfunctionChronic Middle Cerebral Artery OcclusionStenting TreatmentModified Rankin ScaleNational Institutes of Health Stroke ScaleNCT06419283Huizhou Municipal Central Hospital59
终止
不适用
Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)Acute Ischemic StrokeIntracranial StenosisNCT03955835Acandis GmbH27